These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. Besada E; Vik A; Koldingsnes W; Nossent JC Int J Hematol; 2013 Jun; 97(6):800-3. PubMed ID: 23616220 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance. Ojeda-Uribe M; Caron C; Itzhar-Baikian N; Debliquis A Am J Hematol; 2010 May; 85(5):396. PubMed ID: 20425807 [No Abstract] [Full Text] [Related]
7. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Hess G; Wagner V; Kreft A; Heussel CP; Huber C Br J Haematol; 2006 Sep; 134(5):544-5. PubMed ID: 16856889 [No Abstract] [Full Text] [Related]
8. Perspective on the current use of bortezomib in multiple myeloma. San-Miguel J; Bladé J Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272 [No Abstract] [Full Text] [Related]
9. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES Clin Transpl; 2009; ():475-8. PubMed ID: 20524318 [TBL] [Abstract][Full Text] [Related]
10. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report. Patel JK; Everly MJ; Kittleson M; Kobashigawa JA Clin Transpl; 2009; ():347-9. PubMed ID: 20524297 [No Abstract] [Full Text] [Related]
11. Bortezomib rescue in refractory acute humoral rejection--report of a case. Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V Clin Transpl; 2009; ():431-2. PubMed ID: 20524310 [No Abstract] [Full Text] [Related]
12. Acute humoral rejection in a lung recipient: reversion with bortezomib. Neumann J; Tarrasconi H; Bortolotto A; Machuca T; Canabarro R; Sporleder H; Fernandes S; Schio S; Costa C; Camargo S; Sanchez L; Camargo J; Perin F; Felicetti J; Michelon T Transplantation; 2010 Jan; 89(1):125-6. PubMed ID: 20061929 [No Abstract] [Full Text] [Related]
13. A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement. Filosto M; Rossi G; Pelizzari AM; Buzio S; Tentorio M; Broglio L; Mancuso M; Rinaldi M; Scarpelli M; Padovani A J Neurol Sci; 2007 Dec; 263(1-2):40-3. PubMed ID: 17612569 [TBL] [Abstract][Full Text] [Related]
14. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Trivedi HL; Terasaki PI; Feroz A; Vanikar AV; Trivedi VB; Khemchandani SI; Dave SD; Shankar V; Modi PR; Kaneku H; Idica A; Everly MJ Transplantation; 2010 Jul; 90(2):221-2. PubMed ID: 20644455 [No Abstract] [Full Text] [Related]
15. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases. Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M Clin Transpl; 2009; ():361-8. PubMed ID: 20524299 [No Abstract] [Full Text] [Related]
16. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line? Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM Clin Transpl; 2009; ():425-9. PubMed ID: 20524309 [No Abstract] [Full Text] [Related]
17. Proteasome inhibition for treatment of multiple myeloma: clinical update. Stadtmauer EA J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation. Djamali A; Muth BL; Torrealba J; Bloom D; Miller KM; Lorentzen D; Sollinger HW; Pirsch JD; Mezrich JD Clin Transpl; 2009; ():485-90. PubMed ID: 20524320 [No Abstract] [Full Text] [Related]
19. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Gerecitano J; Goy A; Wright J; MacGregor-Cortelli B; Neylon E; Gonen M; Esseltine D; Boral A; Schenkein D; Busam K; Teruya-Feldstein J; Sachs D; O'Connor OA Br J Haematol; 2006 Aug; 134(4):391-8. PubMed ID: 16882131 [TBL] [Abstract][Full Text] [Related]
20. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]